Chevy Chase Trust Holdings LLC lessened its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 2.3% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 96,030 shares of the medical research company's stock after selling 2,248 shares during the period. Chevy Chase Trust Holdings LLC owned 0.05% of IQVIA worth $18,871,000 as of its most recent SEC filing.
Other institutional investors have also added to or reduced their stakes in the company. FMR LLC grew its stake in IQVIA by 38.7% in the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company's stock worth $684,213,000 after buying an additional 804,963 shares in the last quarter. JPMorgan Chase & Co. grew its position in IQVIA by 46.2% in the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company's stock worth $437,378,000 after acquiring an additional 583,396 shares in the last quarter. Impax Asset Management Group plc increased its stake in IQVIA by 9.7% in the third quarter. Impax Asset Management Group plc now owns 1,793,010 shares of the medical research company's stock valued at $423,885,000 after acquiring an additional 157,809 shares during the last quarter. Nordea Investment Management AB increased its position in shares of IQVIA by 47.4% during the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company's stock valued at $277,908,000 after purchasing an additional 452,029 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of IQVIA by 3.4% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,226,083 shares of the medical research company's stock valued at $290,545,000 after buying an additional 39,772 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
IQV has been the subject of several research reports. Leerink Partners reaffirmed an "outperform" rating and issued a $248.00 target price (down previously from $260.00) on shares of IQVIA in a research note on Tuesday, November 19th. Bank of America reduced their target price on shares of IQVIA from $255.00 to $235.00 and set a "buy" rating on the stock in a report on Friday, December 13th. StockNews.com lowered shares of IQVIA from a "buy" rating to a "hold" rating in a research report on Thursday, November 28th. Truist Financial reiterated a "buy" rating and issued a $263.00 price objective (up previously from $261.00) on shares of IQVIA in a report on Monday, February 10th. Finally, TD Cowen dropped their target price on IQVIA from $270.00 to $255.00 and set a "buy" rating for the company in a report on Friday, November 1st. Four equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $251.22.
Get Our Latest Stock Report on IQV
Insiders Place Their Bets
In related news, Director John G. Danhakl bought 1,275 shares of the company's stock in a transaction on Tuesday, December 3rd. The shares were acquired at an average cost of $200.58 per share, with a total value of $255,739.50. Following the completion of the acquisition, the director now owns 1,275 shares of the company's stock, valued at $255,739.50. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 1.60% of the company's stock.
IQVIA Stock Up 1.8 %
Shares of NYSE:IQV traded up $3.39 during trading on Wednesday, hitting $196.54. The stock had a trading volume of 1,700,843 shares, compared to its average volume of 1,411,159. The company has a market capitalization of $34.61 billion, a PE ratio of 26.21, a PEG ratio of 1.98 and a beta of 1.48. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The firm's fifty day moving average is $199.95 and its 200 day moving average is $217.09. IQVIA Holdings Inc. has a 12 month low of $187.62 and a 12 month high of $261.73.
IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Analysts anticipate that IQVIA Holdings Inc. will post 10.86 EPS for the current fiscal year.
IQVIA Profile
(
Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Featured Stories
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
